Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhende Medical Co., Ltd. (603301.SS)
Shaoxing, ZJ, CN
Zhende Medical Co., Ltd. engages in the research and development, production, and sale of medical care and protective equipment in China and internationally. The company offers gauze swab, lap sponge, and fluff gauze swab; non-woven swab; PBT bandage, elastic bandage, crepe bandage, crochet bandage, selvedge bandage, under-cast padding, and fluff gauze roll; dressing set; first aid kit; cotton pad and applicator; and gauze roll and abdominal pad. It also provides surgical gown, scrub suit, warm-up jacket, surgical headwear, and isolation gown; Surgical drape; standard surgical pack and custom procedure pack; equipment cover; OP Tape, hand towel, and fluid collection pouch; latex surgical glove; CSR wrap; and warming blanket system. In addition, the company offers isolation gown, surgical cap, shoe cover, medical mask, and particular respirator; compression bandage and compression stocking; wound care products; pre-filled flush syringes; and ostomy and accessories. Further, it provides respiratory health, home cleaning, IP collaboration, nasal care, protective gear and assistive devices, and personal beauty products. Zhende Medical Co., Ltd. was incorporated in 1994 and is headquartered in Shaoxing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.48% | -11.11% | -9.54% | -4.58% | +5.31% | +18.43% | +300.82% | +144.55% | +68.12% | +473.42% | +473.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+1.5% Q1'26: +0.9% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-31.7% Q1'26: +5.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+3.8% Q1'26: -7.5% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+8.2% Q1'26: +7.4% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+4.7% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-0.8% ★ Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.05× Q1'26: 4.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.43B
est: 1.67B (-14.5%)
|
1.87B
est: 2.10B (-11.2%)
|
10.40B
est: 11.82B (-12.0%)
|
5.09B
est: 5.01B (+1.6%)
|
6.14B
est: 5.96B (+3.0%)
|
4.13B
est: 4.17B (-1.1%)
|
4.26B
est: 4.43B (-3.7%)
|
4.33B
est: 4.62B (-6.2%)
|
5.34B
5.34B – 5.34B
+15.6% YoY
|
6.20B
6.20B – 6.20B
+16.2% YoY
|
| EBITDA |
235.00M
est: 316.99M (-25.9%)
|
294.76M
est: 398.94M (-26.1%)
|
3.63B
est: 2.24B (+62.0%)
|
978.59M
est: 950.22M (+3.0%)
|
1.02B
est: 1.13B (-9.6%)
|
492.77M
est: 791.25M (-37.7%)
|
744.38M
est: 711.69M (+4.6%)
|
653.70M
est: 742.06M (-11.9%)
|
857.62M
857.62M – 857.62M
+15.6% YoY
|
996.33M
996.33M – 996.33M
+16.2% YoY
|
| EBIT |
173.49M
est: 257.47M (-32.6%)
|
229.46M
est: 324.03M (-29.2%)
|
3.56B
est: 1.82B (+95.2%)
|
847.09M
est: 771.78M (+9.8%)
|
836.29M
est: 917.85M (-8.9%)
|
249.81M
est: 642.66M (-61.1%)
|
507.06M
est: 499.81M (+1.5%)
|
356.32M
est: 521.14M (-31.6%)
|
602.30M
602.30M – 602.30M
+15.6% YoY
|
699.71M
699.71M – 699.71M
+16.2% YoY
|
| Net Income |
130.20M
est: 206.00M (-36.8%)
|
156.89M
est: 250.73M (-37.4%)
|
2.55B
est: 4.12B (-38.1%)
|
595.86M
est: 695.96M (-14.4%)
|
679.88M
est: 703.93M (-3.4%)
|
198.40M
est: 201.88M (-1.7%)
|
385.17M
est: 430.74M (-10.6%)
|
260.82M
est: 384.64M (-32.2%)
|
513.73M
513.73M – 513.73M
+33.6% YoY
|
634.92M
634.92M – 634.92M
+23.6% YoY
|
| SGA |
225.28M
est: 274.70M (-18.0%)
|
356.25M
est: 345.72M (+3.0%)
|
865.43M
est: 1.94B (-55.5%)
|
795.32M
est: 823.44M (-3.4%)
|
976.61M
est: 979.28M (-0.3%)
|
890.07M
est: 685.68M (+29.8%)
|
885.80M
est: 718.41M (+23.3%)
|
313.81M
est: 749.08M (-58.1%)
|
865.73M
865.73M – 865.73M
+15.6% YoY
|
1.01B
1.01B – 1.01B
+16.2% YoY
|
| EPS |
0.72
est: 0.78 (-7.2%)
|
0.80
est: 0.94 (-15.2%)
|
12.50
est: 15.50 (-19.4%)
|
2.64
est: 2.62 (+0.8%)
|
2.87
est: 2.65 (+8.3%)
|
0.74
est: 0.76 (-2.6%)
|
1.45
est: 1.64 (-11.3%)
|
0.99
est: 1.46 (-32.2%)
|
1.95
1.95 – 1.95
+33.6% YoY
|
2.41
2.41 – 2.41
+23.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 136.3K | 0.46% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 883.2K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 394.6K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 311.6K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 26.6K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 59.9K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.96M | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 167.1K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 42.5K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 3.42M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baohai Ji | Secretary of the Board of Directors | — | male |
| Dasheng Xu | Deputy GM & Director | — | male |
| Haiping Jin | Chief Financial Officer & Financial Director | — | female |
| Jiangtao Long | Deputy General Manager | — | male |
| Jianguo Lu | Chairman of the Board & GM | — | male |
| Junwu Hu | Deputy General Manager | — | male |
| Shuyan Ma | Head of Accounting & Accounting Supervisor | — | — |
| Zhendong Shen | Director & Deputy GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603301.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
